These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6136054)

  • 41. Effects of anticholinergic agents on patients with tardive dyskinesia and concomitant drug-induced parkinsonism.
    Wirshing WC; Freidenberg DL; Cummings JL; Bartzokis G
    J Clin Psychopharmacol; 1989 Dec; 9(6):407-11. PubMed ID: 2574192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The clinical association of tardive dyskinesia and drug-induced parkinsonism.
    Wolf ME; Chevesich J; Lehrer E; Mosnaim AD
    Biol Psychiatry; 1983 Oct; 18(10):1181-8. PubMed ID: 6140032
    [No Abstract]   [Full Text] [Related]  

  • 43. Gamma-vinyl GABA.
    Hammond EJ; Wilder BJ
    Gen Pharmacol; 1985; 16(5):441-7. PubMed ID: 2932363
    [No Abstract]   [Full Text] [Related]  

  • 44. Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
    Ziegler M; Fournier V; Bathien N; Morselli PL; Rondot P
    Clin Neuropharmacol; 1987 Jun; 10(3):238-46. PubMed ID: 2900682
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.
    Grant SM; Heel RC
    Drugs; 1991 Jun; 41(6):889-926. PubMed ID: 1715266
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Naltrexone treatment of tardive dyskinesia in patients with schizophrenia.
    Wonodi I; Adami H; Sherr J; Avila M; Hong LE; Thaker GK
    J Clin Psychopharmacol; 2004 Aug; 24(4):441-5. PubMed ID: 15232337
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Nordic Dyskinesia Study Group.
    Psychopharmacology (Berl); 1986; 90(4):423-9. PubMed ID: 2880362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical and biochemical effects of calcium-hopantenate on neuroleptics-induced tardive dyskinesia.
    Kashihara K; Ebara T; Yamamoto M; Ogawa T; Harada T; Otsuki S
    Folia Psychiatr Neurol Jpn; 1985; 39(2):147-53. PubMed ID: 2866149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Shoulson I
    Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
    [No Abstract]   [Full Text] [Related]  

  • 52. Tardive dyskinesia and positive symptoms of schizophrenia.
    White T; Brown KW; Woods JP
    Acta Psychiatr Scand; 1991 May; 83(5):377-9. PubMed ID: 1677232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
    Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
    Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is melatonin treatment effective for tardive dyskinesia?
    Shamir E; Barak Y; Plopsky I; Zisapel N; Elizur A; Weizman A
    J Clin Psychiatry; 2000 Aug; 61(8):556-8. PubMed ID: 10982197
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism.
    Korsgaard S; Noring U; Povlsen UJ; Gerlach J
    Clin Neuropharmacol; 1986; 9(1):52-7. PubMed ID: 3470139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy.
    Thaker GK; Nguyen JA; Strauss ME; Jacobson R; Kaup BA; Tamminga CA
    Am J Psychiatry; 1990 Apr; 147(4):445-51. PubMed ID: 1969244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.
    Shriqui CL; Bradwejn J; Annable L; Jones BD
    Am J Psychiatry; 1992 Mar; 149(3):391-3. PubMed ID: 1346951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.